Compare MASS & DHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MASS | DHY |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.6M | 208.3M |
| IPO Year | 2020 | 1998 |
| Metric | MASS | DHY |
|---|---|---|
| Price | $6.10 | $1.89 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 256.8K | ★ 537.5K |
| Earning Date | 03-03-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.47 | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $56,197,000.00 | N/A |
| Revenue This Year | $19.44 | N/A |
| Revenue Next Year | $18.63 | N/A |
| P/E Ratio | $11.33 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.55 | $1.82 |
| 52 Week High | $9.34 | $2.16 |
| Indicator | MASS | DHY |
|---|---|---|
| Relative Strength Index (RSI) | 44.30 | 45.95 |
| Support Level | $5.26 | $1.84 |
| Resistance Level | $6.73 | $2.14 |
| Average True Range (ATR) | 0.35 | 0.03 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 28.81 | 57.89 |
908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.
Credit Suisse High Yield Credit Fund is a diversified, closed-end management investment company. The Fund's principal investment objective is to generate current income. Capital appreciation is a secondary objective, pursued to the extent consistent with the Fund's primary income objective.